CrystalGenomics (China rights to CG-806) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

CrystalGenomics (China rights to CG-806) General Information

Description

A portfolio of licensing rights of an oral, multi-kinase inhibitor that represents a potential therapeutic for patients with acute myeloid leukemia.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • China
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Corporate Office
  • China

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CrystalGenomics (China rights to CG-806) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CrystalGenomics (China rights to CG-806)‘s full profile, request access.

Request a free trial

CrystalGenomics (China rights to CG-806) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CrystalGenomics (China rights to CG-806)‘s full profile, request access.

Request a free trial

CrystalGenomics (China rights to CG-806) FAQs

  • Where is CrystalGenomics (China rights to CG-806) headquartered?

    CrystalGenomics (China rights to CG-806) is headquartered in China.

  • What industry is CrystalGenomics (China rights to CG-806) in?

    CrystalGenomics (China rights to CG-806)’s primary industry is Buildings and Property.

  • Is CrystalGenomics (China rights to CG-806) a private or public company?

    CrystalGenomics (China rights to CG-806) is a Private company.

  • What is the current valuation of CrystalGenomics (China rights to CG-806)?

    The current valuation of CrystalGenomics (China rights to CG-806) is .

  • What is CrystalGenomics (China rights to CG-806)’s current revenue?

    The current revenue for CrystalGenomics (China rights to CG-806) is .

  • Who are CrystalGenomics (China rights to CG-806)’s investors?

    CG Invites has invested in CrystalGenomics (China rights to CG-806).

  • When was CrystalGenomics (China rights to CG-806) acquired?

    CrystalGenomics (China rights to CG-806) was acquired on 14-Jun-2018.

  • Who acquired CrystalGenomics (China rights to CG-806)?

    CrystalGenomics (China rights to CG-806) was acquired by Aptose Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process